Andrew Bogut admitted he was still getting to grips with referees in Australia as Sydney took their record to 2-2.
Reported by Brisbane Times 1 hour ago.
Kings off bottom of NBL after thrilling overtime win over Taipans
↧
↧
VAR in A-League spotlight again as Sydney beats Wanderers
SYDNEY (AP) — The video assistant referee system stirred new controversy in Australia's A-League when Western Sydney Wanderers coach Markus Babbel was red carded for his angry reaction to a decision in his team's 2-0 derby loss to...
Reported by New Zealand Herald 2 hours ago.
↧
Young Australians miss Fast5 final, claim third place
New Zealand beat Jamaica in a thrilling grand final, after an early loss to England killed off Australia's hopes of winning the Fast5 Netball World Series.
Reported by Brisbane Times 33 minutes ago.
↧
First Aust air defence members honoured
Australia's first air defence force members have been remembered at a ceremony in Melbourne ahead of the centenary of the end of World War I.
Reported by SBS 31 minutes ago.
↧
How NSW compares: best on budget, poor on housing
There are surprising variations in the performance of Australia's states.
Reported by Brisbane Times 30 minutes ago.
↧
↧
Lenient punishment in past led to Cape Town ball-tampering fallout, says Steve Waugh
The absence of stringent punishment for ball tampering encouraged players to cross the line, says former Australia captain Steve Waugh, who blames the authorities for the 'sandpaper gate' that led to suspension of Steve Smith and David Warner.
Reported by DNA 21 minutes ago.
↧
Cricket Australia accused of creating cheating culture
Cricket Australia (CA) has been accused of creating a "win-at-all-costs" environment which led to a recent cheating scandal and the reputation of one of the country's most loved sports being damaged.
Reported by Sify 2 hours ago.
↧
Malcolm Turnbull jets in for crucial talks with Joko Widodo
Malcolm Turnbull will meet Joko Widodo in a bid to repair bilateral relations, which have been damaged by suggestions Australia could move its Israeli embassy.
Reported by Brisbane Times 1 hour ago.
↧
Musgrave Minerals extends high-grade gold at Cue Gold Project in WA
Musgrave Minerals Ltd (ASX:MGV) has extended high-grade gold mineralisation with reverse circulation (RC) drilling at the Lake Austin North prospect within its Cue Gold Project. The southern-most RC hole intersected the best result to date in the A zone of the prospect, grading 94 metres at 2.4 g/t gold from 156 metres. Within this intersection was higher grade assays of 52 metres at 4.1 g/t including 12 metres at 8.8 g/t from 204 metres and 6 metres at 6.3 g/t from 240 metres. Diamond drilling has begun at Lake Austin North and first assay results are expected in early December. Musgrave managing director Rob Waugh said: “Drill hole 18MORC057 has returned another thick high-grade result and delivered our best intercept to date at A zone. “It is the most southerly hole drilled to date testing the basement on A zone and the results indicate the system is open to the south as well as to the north and at depth. “Lake Austin North is proving to be a large, well-mineralised system and the current diamond drilling program will aim to further outline the size and grade of this new and exciting gold discovery.” READ: Musgrave Minerals to follow-up high-grade gold results at Cue project in Western Australia The hole drilled in A zone was terminated in mineralisation at the depth capacity of the rig, with the mineralisation open up-dip, down-dip and along strike to the north and south. The hole also intersected an upper regolith gold halo of 30 metres at 0.3 g/t from 102 metres. Drilling at Lake Austin’s C zone was terminated early and did not reach the planned depth. Mineralisation at C zone is hosted within a silica-sericite-pyrite altered tonalite intrusive with quartz veining. Orientation and extent of the gold mineralisation is unknown and Musgrave intends to test the target with aircore drilling.
Reported by Proactive Investors 2 hours ago.
↧
↧
Turnbull takes a swipe at Morrison's Israeli embassy plan
Malcolm Turnbull spoke after meeting Indonesian President Joko Widodo, less than two weeks after Australia announced it could move its Israeli embassy from Tel Aviv to Jerusalem.
Reported by Brisbane Times 1 hour ago.
↧
Cricket Australia branded 'arrogant' in post-cheating scandal review
The long-awaited review of Cricket Australia has painted a grim view of the governing body, its arrogance and inability to crackdown on player behaviour.
Reported by SBS 1 hour ago.
↧
U.S.-China Trade War Impacting Companies Worldwide, AmCham South China Study Reveals
GUANGZHOU, China, Oct. 29, 2018 /PRNewswire/ -- The U.S.-China trade war and its tariff-counter-tariff style of negotiation is impacting not just the Chinese or U.S. businesses but also companies from many other countries as well, according to the new Special Report on the Impact of U.S. and Chinese Tariffs conducted by the American Chamber of Commerce in South China (AmCham South China).Scan to download Special Report on the Impact of U.S. and Chinese Tariffs by AmCham South China.The Special Report on the Impact of U.S. and Chinese Tariffs was conducted between September 21 and October 10, shortly after the additional US$200 billion in tariffs on Chinese products imposed by the Trump administration and the tariffs on US$60 billion on the U.S. products by the Chinese government. A total of 219 companies participated, of which one third are engaged in the manufacturing industry, more than one half in the service sector, and around one seventh in other industries. Roughly 95 percent of respondents have operations in China.
The Study shows the combined tariffs have negatively impacted various industries and companies not only from the U.S. and China, but also those from different origins, affecting business operations and resulting in substantial loss of business volume and market share. Participants in the Study include companies from China, U.S., Canada, European Union, Japan, Korea, Southeast Asia, Australia, New Zealand, and Hong Kong and Macau SARs. Nearly a half of the respondents report that they have lost market share to companies from other countries due to the trade war. Vietnam, Germany, and Japan are generally considered as the top three competitors particularly for the U.S. companies in imports and exports, while for the Chinese the competitions come from Vietnam, India, and Korea. Among all the participants, manufacturing companies are suffering more losses of market share than those in agribusiness.
Chamber president Dr. Harley Seyedin said the immediate impact has not yet been completely felt by these businesses since much of the orders for export items from both countries had been placed long in advance of the dispute and in many cases few, if any, alternative sourcing options are available. "The primary concerns at this point is that consumers in both nations may have to pay slightly more for many items now and likely much higher prices in the not too distant future," Seyedin added.
According to the Study, although plans for relocation of manufacturing lines outside of China are considered by a majority of respondents, only very few participants will give up the Chinese market. Instead, most of the respondents see the expansion of the Chinese market as one of the most important remedies for the imposed tariffs, which sheds light on the priority of the Chinese market. Meanwhile, it is interesting to note that just one percent of the Study participants indicate any plans for establishing manufacturing in North America.
Both the U.S. and Chinese companies harbor low confidence in U.S.-China relations. Negative opinions towards imposed tariffs are widely shared by the business community. Meanwhile, more U.S. companies report that they are hurt in the trade tensions than their Chinese counterparts, particularly in terms of practical impact on the business operation, loss of business volume and market share. Nevertheless, the U.S. companies are more active in reacting towards the impact of the trade disputes.
Seyedin said he is less worried about the present than he is about the future ramifications between the U.S. and China. "What worries me the most is not so much the immediate impact," Seyedin added, "but the potential long-term loss of access by Chinese companies to the U.S. market and, as a result, American companies' access to a market that will eventually have five times as many consumers as the U.S." He hopes that "the Study, representing the factual points of view of participating companies from countries spanning the globe, will cause the leaders from both sides of the equation to pause and rethink their strategies. We suggest, as countless others have, that all differences can and should be resolved through friendly discussions."
*About The American Chamber of Commerce in South China*
The American Chamber of Commerce in South China (AmCham South China) is a non-partisan, non-profit organization dedicated to facilitating bilateral trade between the United States and the People's Republic of China. Certified in 1995 by its parent organization, the U.S. Chamber of Commerce in Washington, D.C., AmCham South China represents more than 2,300 corporate and individual members, is governed by a fully-independent Board of Governors elected from its membership, and provides dynamic, on-the-ground support for American and International companies doing business in South China. In 2017, AmCham South China hosted nearly 10,000 business executives, government leaders and journalists from around the world at its briefings, seminars, committee meetings and social gatherings.
For Additional Information, please contact:
Ms. Rachel Chen
Communications Manager
The American Chamber of Commerce in South China
Tel: +86-8335-1476-39
E-mail: rchen@amcham-southchina.org
View original content to download multimedia:http://www.prnewswire.com/news-releases/us-china-trade-war-impacting-companies-worldwide-amcham-south-china-study-reveals-300739262.html Reported by PR Newswire Asia 2 hours ago.
↧
Auriant Mining AB (publ.) publishes 9m 2018 operational update
Auriant Mining AB (publ.) resumed mining at Tardan in July as planned. In Q3 2018, the Company mined 65,000 tonnes of ore with an average grade 2.79 g/t and this ore was stacked on the heap leach. Total gold production from the heap leach for 9months of 2018 was 208.3 kg (6,632 oz), compared to 538.9 kg (17,326 oz) in the same period in the previous year (-61%). The main reason for this decline in production was that no mining or crushing operations were carried out in the first 6 months of 2018, in order to save the ore for the more efficient CIL plant, for when it starts to operate in 2019. The Company expects that Tardan production for the whole of 2018 will be 380 kg, (12,217 oz) which is slightly above the previously announced forecast of 350 kg (11,252 oz)
The Tardan CIL project is proceeding according to plan. As recently announced, the CIL project complies with Russian Federation environmental protection standards and has been passed by the State Ecological Expertise. The Company aims to start production from the CIL plant in Q3 2019 and produce 1 tonne (32,150 oz) of gold in the year.
In May 2018, alluvial production was resumed at Solcocon. This production is 100% outsourced and generates a net margin of 29% of sales for the Company. In the current period, the Company engaged 2 contractors working on 2 placers, while 1 contractor was involved in 2017. During the reporting period, the Company produced 62.7 kg (2,015 oz) of alluvial gold compared to 41.2 kg (1,324 oz) produced in the previous period. Production at Solcocon in July was interrupted by heavy rainfall, which has led to widespread flooding in the Zabaikalsky region. Despite growth in production in Q3 2018 as compared to Q2 2018 (46.6 kg vs 16.1 kg) and continued mining in October as the weather was favourable, the alluvial production forecast of 150 kg (4,822 oz) will not be met. 2018 production is expected to reach 75 kg (2,411 oz).
For more information, please contact:
Sergey Ustimenko, CEO
tel: +7 495 109 02 82
e-mail: sergey.ustimenko@auriant.com
Company name: Auriant Mining AB
Short name: AUR
ISIN-code: SE0001337213
Website: www.auriant.com
Twitter: @auriantmining
Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in Zabaikalye and the Republics of Khakassia and Tyva. The company has currently four assets, including one operating mine (Tardan), one early stage exploration asset and two development assets.
Since July 19, 2010, Auriant Mining´s shares are traded on First North Premier at the NASDAQ OMX Nordic Exchange under the short name AUR. For more information please visit www.auriant.com. Mangold Fondkommission is Certified Adviser to Auriant, for more information please call +46 8 503 015 50 or visit www.mangold.se.
This information is information that Auriant Mining AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 CET on October 29^th , 2018.
*Cautionary Statement:* Statements and assumptions made in this report with respect to Auriant Mining AB’s (“AUR”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of AUR. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where AUR operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) AUR’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) exchange rates, particularly between the Russian rouble and the U.S. dollar. In the light of the many risks and uncertainties surrounding any gold production and exploration company at an early stage of its development, the actual results could differ materially from those presented and forecast in this report. AUR assumes no unconditional obligation to immediately update any such statements and/or forecasts
This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Nothing in this press release should be considered as an offer to invest or otherwise trade in shares of Auriant Mining AB (publ). The proposed issue will not be directed at residents or those living in the United States, Australia, Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action would require further prospectus, other offering documentation, registration or other measures beyond those required by Swedish law. No securities will be registered under the United States Securities Act of 1933, a similar law in any state in the United States, or under any provincial law in Canada, nor under the applicable law of another country.
*Attachment*
· 9m 2018 Operational update_ENG Reported by GlobeNewswire 2 hours ago.
The Tardan CIL project is proceeding according to plan. As recently announced, the CIL project complies with Russian Federation environmental protection standards and has been passed by the State Ecological Expertise. The Company aims to start production from the CIL plant in Q3 2019 and produce 1 tonne (32,150 oz) of gold in the year.
In May 2018, alluvial production was resumed at Solcocon. This production is 100% outsourced and generates a net margin of 29% of sales for the Company. In the current period, the Company engaged 2 contractors working on 2 placers, while 1 contractor was involved in 2017. During the reporting period, the Company produced 62.7 kg (2,015 oz) of alluvial gold compared to 41.2 kg (1,324 oz) produced in the previous period. Production at Solcocon in July was interrupted by heavy rainfall, which has led to widespread flooding in the Zabaikalsky region. Despite growth in production in Q3 2018 as compared to Q2 2018 (46.6 kg vs 16.1 kg) and continued mining in October as the weather was favourable, the alluvial production forecast of 150 kg (4,822 oz) will not be met. 2018 production is expected to reach 75 kg (2,411 oz).
For more information, please contact:
Sergey Ustimenko, CEO
tel: +7 495 109 02 82
e-mail: sergey.ustimenko@auriant.com
Company name: Auriant Mining AB
Short name: AUR
ISIN-code: SE0001337213
Website: www.auriant.com
Twitter: @auriantmining
Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in Zabaikalye and the Republics of Khakassia and Tyva. The company has currently four assets, including one operating mine (Tardan), one early stage exploration asset and two development assets.
Since July 19, 2010, Auriant Mining´s shares are traded on First North Premier at the NASDAQ OMX Nordic Exchange under the short name AUR. For more information please visit www.auriant.com. Mangold Fondkommission is Certified Adviser to Auriant, for more information please call +46 8 503 015 50 or visit www.mangold.se.
This information is information that Auriant Mining AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 CET on October 29^th , 2018.
*Cautionary Statement:* Statements and assumptions made in this report with respect to Auriant Mining AB’s (“AUR”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of AUR. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where AUR operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) AUR’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) exchange rates, particularly between the Russian rouble and the U.S. dollar. In the light of the many risks and uncertainties surrounding any gold production and exploration company at an early stage of its development, the actual results could differ materially from those presented and forecast in this report. AUR assumes no unconditional obligation to immediately update any such statements and/or forecasts
This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Nothing in this press release should be considered as an offer to invest or otherwise trade in shares of Auriant Mining AB (publ). The proposed issue will not be directed at residents or those living in the United States, Australia, Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action would require further prospectus, other offering documentation, registration or other measures beyond those required by Swedish law. No securities will be registered under the United States Securities Act of 1933, a similar law in any state in the United States, or under any provincial law in Canada, nor under the applicable law of another country.
*Attachment*
· 9m 2018 Operational update_ENG Reported by GlobeNewswire 2 hours ago.
↧
↧
Pakistan retains 15-member T20 squad for series against NZ
ISLAMABAD (AP) — Top-ranked Pakistan has retained the same 15-member squad that swept Australia 3-0 for the upcoming three-match Twenty20 series against New Zealand.The series begins in Abu Dhabi, United Arab Emirates on Wednesday...
Reported by New Zealand Herald 2 hours ago.
↧
Our cricketers can rise from the ashes
Australia’s bearers of that fabled green cap can emerge enhanced and even, once again, revered. Another ethical collapse, though, would be an epic nightmare.
Reported by The Age 1 hour ago.
↧
Meghan Markle trainers: The pregnant Duchess of Sussex shuns royal tradition again with designer Adidas trainers as she goes casual in New Zealand
Prince Harry, Duke of Sussex and Meghan Markle, Duchess of Sussex visit Abel Tasman National Park [Getty] Meghan Markle and Prince Harry have arrived in New Zealand for the last leg of their royal tour. The Duke and Duchess of Sussex are on a 16 day royal tour of Australia, Fiji, Tonga and New Zealand and announced they were expecting their first baby during the trip, with a due date of spring 2019. Pregnant Meghan has been keeping busy, attending nearly all of the ...
Reported by OK! 1 hour ago.
↧
Opthea Provides Update on Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum
MELBOURNE, Australia, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to provide an update on “Beyond anti-VEGF-A for Retinal Diseases,” a Company hosted symposium focused on next generation treatments for ‘back of the eye’ conditions, wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The details of the event are as follows:
· *Date:* Tuesday, November 6^th, 2018
· *Location:* Parker New York Hotel (formerly Parker Meridian) in New York City
· *Start time/duration:* 12:00-2:00PM EST
· *Moderator:* Yigal Nochomovitz, Ph.D., Director of Biotechnology Research at Citigroup
*The agenda will include:*
· Presentations on the wet AMD and DME treatment landscapes and practice experiences by Dr. Arshad Khanani of Sierra Eye Associates and Dr. Rishi Singh of the Cleveland Clinic
· Briefing on the unique mechanism of action and clinical experience with Opthea’s lead molecule OPT-302, by Dr. Nathan Steinle of California Retina Consultants
· Interactive panel discussion moderated by Dr. Yigal Nochomovitz, in which audience participation will be encouraged
“As an emerging company in ophthalmology, with Phase 2 clinical trials ongoing in both wet AMD and DME, it is a pleasure to host this symposium focused on understanding the importance of improving treatment solutions for these two debilitating retinal diseases,” commented Dr. Megan Baldwin, Chief Executive Officer and Managing Director of Opthea.
To register for this event, please send an email request to IR@opthea.com with your name, company and phone number. The Parker Hotel is located at 119 West 56^th Street, New York, N.Y. 10019-3318.
*About OPT-302*
OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A (eg. Lucentis^®/Eylea^®). Combination therapy of OPT-302 and a VEGF-A inhibitor achieves more complete blockade of members of the VEGF family, blocks mechanisms contributing to sub-optimal response to selective VEGF-A inhibitors and has the potential to improve vision outcomes by more completely inhibiting the pathways involved in disease progression.
Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 wet AMD patients as a monotherapy and in combination with Lucentis^®. The trial was conducted under an FDA approved IND at 14 US clinical sites. The purpose of the trial was to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis^® in patients with wet age related macular degeneration (AMD). Of the 51 patients enrolled, 25 were treatment naïve and 26 had received prior intravitreal anti-VEGF-A therapy.
Further details on Opthea’s clinical trials can be found at www.clinicaltrials.gov, clinical trial identifiers: NCT02543229 (Phase 1/2a wet AMD); NCT03345082 (Phase 2b wet AMD) and NCT03397264 (Phase 1b/2a DME). Additional information on Opthea’s technology and clinical trials can found on Opthea’s website www.opthea.com.
*About Wet AMD and DME*
Wet (neovascular) age-related macular degeneration, or wet AMD, is a disease characterised by the loss of vision of the middle of the visual field caused by degeneration of the central portion of the retina (the macula). Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. Wet AMD is the leading cause of blindness in the developed world in individuals aged 50 years or older. The prevalence of AMD is increasing annually as the population ages. Without treatment, wet AMD patients often experience a chronic, rapid decline in visual acuity and increase in retinal fluid.
DME is the leading cause of blindness in diabetics and is estimated to affect approximately 2 million people globally^1,2,3. Chronically elevated blood glucose levels in Type 1 and Type 2 diabetics can lead to inflammation, vascular dysfunction and hypoxia, causing upregulation of members of the VEGF family of growth factors. VEGFs, including VEGF-A and VEGF-C, stimulate vascular permeability or vascular leakage, leading to fluid accumulation in the macula at the back of the eye and retinal thickening which affects vision. Existing standard of care treatments for DME are limited and include inhibitors of VEGF-A (Lucentis^®, Eylea^®), steroids and laser therapy. Despite these treatments, many patients remain refractory and have a sub-optimal response to therapy with persistent fluid and impaired vision. OPT-302 blocks VEGF-C and VEGF-D, which cause vessels to grow and leak. Used in combination with a VEGF-A inhibitor, OPT-302 has the potential to improve clinical outcomes in DME patients.
Existing standard of care treatments for DME and wet AMD include agents that inhibit VEGF-A, but not VEGF-C or VEGF-D. Sales of the drug Lucentis^® (Roche/Novartis), which targets VEGF-A, were over $US3.4BN in 2017. Sales of Eylea^® (Regeneron/Bayer), which also targets VEGF-A but not VEGF-C/-D were over $US5.9BN in 2017. Many patients receiving Lucentis^®/Eylea^® are classified as non-responders or ‘poor’ responders and do not experience a significant gain in vision and/or have persistent retinal vascular leakage. There is great opportunity to improve patient responses by targeting more than one factor involved in disease progression. Existing therapies, such as Lucentis^® and Eylea^®, target VEGF-A that promotes blood vessel growth and leakage through its receptor VEGFR-2. VEGF-C can also induce angiogenesis and vessel leakage through the same receptor as well as through an independent pathway. Combined inhibition of VEGF-A and VEGF-C/-D, has the potential to improve patient response by more effective inhibition of the pathways involved in disease progression.
*About Opthea Limited*
Opthea (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea’s product development programs are focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for ‘back of the eye’ disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
*Inherent risks of Investment in Biotechnology Companies*
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
*Forward-looking statements*
Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Opthea undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.
^1 Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 12: 346-354, 2012.
^2 Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision. 2:17, 2015.
^3 Managing Diabetic Eye Disease in Clinical Practice. Singh RP (ed). Springer International Publishing 2015.
Company & Media Enquiries: Join our email database to receive program updates:
Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 447 788 674
megan.baldwin@opthea.com Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com
Australia:
Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333 U.S.A. & International:
Jason Wong
Blueprint Life Science Group
Tel: +1 415 375 3340, Ext 4
Jwong@bplifescience.com
Reported by GlobeNewswire 1 hour ago.
· *Date:* Tuesday, November 6^th, 2018
· *Location:* Parker New York Hotel (formerly Parker Meridian) in New York City
· *Start time/duration:* 12:00-2:00PM EST
· *Moderator:* Yigal Nochomovitz, Ph.D., Director of Biotechnology Research at Citigroup
*The agenda will include:*
· Presentations on the wet AMD and DME treatment landscapes and practice experiences by Dr. Arshad Khanani of Sierra Eye Associates and Dr. Rishi Singh of the Cleveland Clinic
· Briefing on the unique mechanism of action and clinical experience with Opthea’s lead molecule OPT-302, by Dr. Nathan Steinle of California Retina Consultants
· Interactive panel discussion moderated by Dr. Yigal Nochomovitz, in which audience participation will be encouraged
“As an emerging company in ophthalmology, with Phase 2 clinical trials ongoing in both wet AMD and DME, it is a pleasure to host this symposium focused on understanding the importance of improving treatment solutions for these two debilitating retinal diseases,” commented Dr. Megan Baldwin, Chief Executive Officer and Managing Director of Opthea.
To register for this event, please send an email request to IR@opthea.com with your name, company and phone number. The Parker Hotel is located at 119 West 56^th Street, New York, N.Y. 10019-3318.
*About OPT-302*
OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A (eg. Lucentis^®/Eylea^®). Combination therapy of OPT-302 and a VEGF-A inhibitor achieves more complete blockade of members of the VEGF family, blocks mechanisms contributing to sub-optimal response to selective VEGF-A inhibitors and has the potential to improve vision outcomes by more completely inhibiting the pathways involved in disease progression.
Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 wet AMD patients as a monotherapy and in combination with Lucentis^®. The trial was conducted under an FDA approved IND at 14 US clinical sites. The purpose of the trial was to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis^® in patients with wet age related macular degeneration (AMD). Of the 51 patients enrolled, 25 were treatment naïve and 26 had received prior intravitreal anti-VEGF-A therapy.
Further details on Opthea’s clinical trials can be found at www.clinicaltrials.gov, clinical trial identifiers: NCT02543229 (Phase 1/2a wet AMD); NCT03345082 (Phase 2b wet AMD) and NCT03397264 (Phase 1b/2a DME). Additional information on Opthea’s technology and clinical trials can found on Opthea’s website www.opthea.com.
*About Wet AMD and DME*
Wet (neovascular) age-related macular degeneration, or wet AMD, is a disease characterised by the loss of vision of the middle of the visual field caused by degeneration of the central portion of the retina (the macula). Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. Wet AMD is the leading cause of blindness in the developed world in individuals aged 50 years or older. The prevalence of AMD is increasing annually as the population ages. Without treatment, wet AMD patients often experience a chronic, rapid decline in visual acuity and increase in retinal fluid.
DME is the leading cause of blindness in diabetics and is estimated to affect approximately 2 million people globally^1,2,3. Chronically elevated blood glucose levels in Type 1 and Type 2 diabetics can lead to inflammation, vascular dysfunction and hypoxia, causing upregulation of members of the VEGF family of growth factors. VEGFs, including VEGF-A and VEGF-C, stimulate vascular permeability or vascular leakage, leading to fluid accumulation in the macula at the back of the eye and retinal thickening which affects vision. Existing standard of care treatments for DME are limited and include inhibitors of VEGF-A (Lucentis^®, Eylea^®), steroids and laser therapy. Despite these treatments, many patients remain refractory and have a sub-optimal response to therapy with persistent fluid and impaired vision. OPT-302 blocks VEGF-C and VEGF-D, which cause vessels to grow and leak. Used in combination with a VEGF-A inhibitor, OPT-302 has the potential to improve clinical outcomes in DME patients.
Existing standard of care treatments for DME and wet AMD include agents that inhibit VEGF-A, but not VEGF-C or VEGF-D. Sales of the drug Lucentis^® (Roche/Novartis), which targets VEGF-A, were over $US3.4BN in 2017. Sales of Eylea^® (Regeneron/Bayer), which also targets VEGF-A but not VEGF-C/-D were over $US5.9BN in 2017. Many patients receiving Lucentis^®/Eylea^® are classified as non-responders or ‘poor’ responders and do not experience a significant gain in vision and/or have persistent retinal vascular leakage. There is great opportunity to improve patient responses by targeting more than one factor involved in disease progression. Existing therapies, such as Lucentis^® and Eylea^®, target VEGF-A that promotes blood vessel growth and leakage through its receptor VEGFR-2. VEGF-C can also induce angiogenesis and vessel leakage through the same receptor as well as through an independent pathway. Combined inhibition of VEGF-A and VEGF-C/-D, has the potential to improve patient response by more effective inhibition of the pathways involved in disease progression.
*About Opthea Limited*
Opthea (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea’s product development programs are focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for ‘back of the eye’ disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
*Inherent risks of Investment in Biotechnology Companies*
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
*Forward-looking statements*
Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Opthea undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.
^1 Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 12: 346-354, 2012.
^2 Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision. 2:17, 2015.
^3 Managing Diabetic Eye Disease in Clinical Practice. Singh RP (ed). Springer International Publishing 2015.
Company & Media Enquiries: Join our email database to receive program updates:
Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 447 788 674
megan.baldwin@opthea.com Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com
Australia:
Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333 U.S.A. & International:
Jason Wong
Blueprint Life Science Group
Tel: +1 415 375 3340, Ext 4
Jwong@bplifescience.com
Reported by GlobeNewswire 1 hour ago.
↧
↧
Circuit Breaker Market revenue worth over $21 billion by 2024: Global Market Insights, Inc.
Global Circuit Breaker Market By Voltage, By Rated Voltage, By Rated Current, By Application, By End Use, Regional Outlook (U.S., Canada, Mexico, France, Germany, Spain, Italy, UK, Austria, Netherlands, Sweden, Russia, Belgium, Denmark, Switzerland, China, India, Japan, South Korea, Australia, Indonesia, Philippines, New Zealand, Malaysia, Thailand, Singapore, Saudi Arabia, UAE, Qatar, Kuwait, Oman, Lebanon, Turkey, Jordan, South Africa, Nigeria, Morocco, Azerbaijan, Belarus, Ukraine, Kazakhstan, Brazil, Argentina, Peru), Application Potential, Competitive Market Share & Forecast, 2018 – 2024
Sellbyville, Delaware, Oct. 29, 2018 (GLOBE NEWSWIRE) --Global Circuit Breakers Market is expected to cross USD 21 Billion by 2024, as reported in the latest study by Global Market Insights, Inc. Affirmative regulatory mandates toward the development of cross border electric infrastructure to sustain the rising demand for the refurbishment of ageing transmission network will foster the circuit breaker market. Favorable policy interventions coupled with positive sectoral amendments supported by rapid economic escalation have further instigated the overall energy industry. Aggregate technical & commercial (AT&C) coagulated by accruing circuit losses, result in deficiency in terms of revenue & energy realization which in turn will complement the integration of effective transmission & distribution components.
> 550 kV units in the current industrial scenario, have gained an upsurge subject to the ongoing expansion of ultra-high-tension (UHT) electric networks to endure losses accumulated from long-distance power supply. Advance product specifications, curtailment ability for over-currents, cost along with ease of installation are essential factors driving the product penetration. Regulatory inclination towards the deployment of HVDC transmission infrastructure to meet cross-border demand for electricity will further complement the circuit breaker market outlook.
*Request for a sample of this research report @ *https://www.gminsights.com/request-sample/detail/1172
Europe market will gain escalation subject to the stringent energy efficiency mandates along with rising share of sustainable electricity networks. Regulators with an aim to institute a potent energy mechanism have been channelizing funds to befit their networks for effective electricity generation & supply. European Union’s policy objectives comprehend, investment & restructuring of the existing grid infrastructure to integrate renewable resources and sustain the leap in energy demand.
> 4,500 Ampere circuit breaker market will exceed an annual installation of 1 million units by 2024. Large scale industrial expansion along with product viability across utility deployed transmission & distribution lines will positively sway the industry dynamics. These units behold significant installations across inter-state and cross border transmission networks exhibiting comparatively higher ampacity with an aim to ensure network & operational security across the regional grid infrastructure.
Browse key industry insights spread across 1550 pages with 2626 market data tables & 21 figures & charts from the report, *“Global Circuit Breaker Market” *in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/circuit-breakers-market
The circuit breaker market in the recent years has gained impetus with an influx of advanced, flexible, and secure product specifications. Although the manufacturers and suppliers have consistently been streamlining their R&D investments to expand and enhance product portfolios, fresh investments from leading participants to incorporate a versatile technological platform has been a considerable breakthrough. In addition, favorable consumer tendencies toward the deployment of the products with an aim to safeguard the operational environment along with enhancing the life expectancy of the electric network have further added to the industry advantage.
Electric protection equipment’s in the current industrial regime have gained prominence subject to their product versatility and diverse applicability across power distribution networks. These products have gained penetration across a pool of applications hovering from small residential electricity networks to large utility-aided distribution infrastructure. With increasing adoption, manufacturers and industry participants have aligned their focus on the development and sustainable distribution of the products. Favorable consumer tendencies and product versatility favored by cost-effective product configurations will fuel the global market potential.
Eminent players across the global market comprise of Schneider Electric, Eaton, ABB, Mitsubishi, Toshiba, Mersen S.A, Hitachi, Crompton Greaves, Siemens, Powell Industries, Fuji Electric, Meidensha, Hubbell, TE Connectivity, L&T, and BEL Fuse.
*Make an inquiry for purchasing this report @* https://www.gminsights.com/inquiry-before-buying/1172
*Browse Related Reports:*
· *Transfer Switch Market Size 2017 – 2024*
Global Transfer Switch Market for 2016 was valued at over USD 1 billion and is set to witness annual installation of 5 million units by 2024. Ongoing reforms toward the replacement of conventional generating technologies with sustainable energy sources across developed economies will drive the global market growth.
https://www.gminsights.com/industry-analysis/transfer-switch-market
· *Power Transmission Component Market Size 2017 – 2024*
Power Transmission Component Market revenue for 2016 was valued at over USD 60 billion and is set to witness growth over 6% by 2024. Favourable policy interventions along with supportive sectoral reforms supporting the integration of energy efficient components will escalate the market growth.
https://www.gminsights.com/industry-analysis/power-transmission-components-market
*About Global Market Insights*
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.
CONTACT: Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: http://exsoft.org/category/science-environment/ Reported by GlobeNewswire 1 hour ago.
Sellbyville, Delaware, Oct. 29, 2018 (GLOBE NEWSWIRE) --Global Circuit Breakers Market is expected to cross USD 21 Billion by 2024, as reported in the latest study by Global Market Insights, Inc. Affirmative regulatory mandates toward the development of cross border electric infrastructure to sustain the rising demand for the refurbishment of ageing transmission network will foster the circuit breaker market. Favorable policy interventions coupled with positive sectoral amendments supported by rapid economic escalation have further instigated the overall energy industry. Aggregate technical & commercial (AT&C) coagulated by accruing circuit losses, result in deficiency in terms of revenue & energy realization which in turn will complement the integration of effective transmission & distribution components.
> 550 kV units in the current industrial scenario, have gained an upsurge subject to the ongoing expansion of ultra-high-tension (UHT) electric networks to endure losses accumulated from long-distance power supply. Advance product specifications, curtailment ability for over-currents, cost along with ease of installation are essential factors driving the product penetration. Regulatory inclination towards the deployment of HVDC transmission infrastructure to meet cross-border demand for electricity will further complement the circuit breaker market outlook.
*Request for a sample of this research report @ *https://www.gminsights.com/request-sample/detail/1172
Europe market will gain escalation subject to the stringent energy efficiency mandates along with rising share of sustainable electricity networks. Regulators with an aim to institute a potent energy mechanism have been channelizing funds to befit their networks for effective electricity generation & supply. European Union’s policy objectives comprehend, investment & restructuring of the existing grid infrastructure to integrate renewable resources and sustain the leap in energy demand.
> 4,500 Ampere circuit breaker market will exceed an annual installation of 1 million units by 2024. Large scale industrial expansion along with product viability across utility deployed transmission & distribution lines will positively sway the industry dynamics. These units behold significant installations across inter-state and cross border transmission networks exhibiting comparatively higher ampacity with an aim to ensure network & operational security across the regional grid infrastructure.
Browse key industry insights spread across 1550 pages with 2626 market data tables & 21 figures & charts from the report, *“Global Circuit Breaker Market” *in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/circuit-breakers-market
The circuit breaker market in the recent years has gained impetus with an influx of advanced, flexible, and secure product specifications. Although the manufacturers and suppliers have consistently been streamlining their R&D investments to expand and enhance product portfolios, fresh investments from leading participants to incorporate a versatile technological platform has been a considerable breakthrough. In addition, favorable consumer tendencies toward the deployment of the products with an aim to safeguard the operational environment along with enhancing the life expectancy of the electric network have further added to the industry advantage.
Electric protection equipment’s in the current industrial regime have gained prominence subject to their product versatility and diverse applicability across power distribution networks. These products have gained penetration across a pool of applications hovering from small residential electricity networks to large utility-aided distribution infrastructure. With increasing adoption, manufacturers and industry participants have aligned their focus on the development and sustainable distribution of the products. Favorable consumer tendencies and product versatility favored by cost-effective product configurations will fuel the global market potential.
Eminent players across the global market comprise of Schneider Electric, Eaton, ABB, Mitsubishi, Toshiba, Mersen S.A, Hitachi, Crompton Greaves, Siemens, Powell Industries, Fuji Electric, Meidensha, Hubbell, TE Connectivity, L&T, and BEL Fuse.
*Make an inquiry for purchasing this report @* https://www.gminsights.com/inquiry-before-buying/1172
*Browse Related Reports:*
· *Transfer Switch Market Size 2017 – 2024*
Global Transfer Switch Market for 2016 was valued at over USD 1 billion and is set to witness annual installation of 5 million units by 2024. Ongoing reforms toward the replacement of conventional generating technologies with sustainable energy sources across developed economies will drive the global market growth.
https://www.gminsights.com/industry-analysis/transfer-switch-market
· *Power Transmission Component Market Size 2017 – 2024*
Power Transmission Component Market revenue for 2016 was valued at over USD 60 billion and is set to witness growth over 6% by 2024. Favourable policy interventions along with supportive sectoral reforms supporting the integration of energy efficient components will escalate the market growth.
https://www.gminsights.com/industry-analysis/power-transmission-components-market
*About Global Market Insights*
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.
CONTACT: Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: http://exsoft.org/category/science-environment/ Reported by GlobeNewswire 1 hour ago.
↧
Sport24.co.za | Pakistan keep winning combination for NZ T20s
Pakistan's selectors have kept the same winning combination against New Zealand for the three-match Twenty20 series which whitewashed Australia in United Arab Emirates.
Reported by News24 1 hour ago.
↧
Australia is the latest country whose banks are planning to abandon London as Brexit looms
**· *Australia's banks are beginning to put in motion plans to shift staff and other assets out of London after Brexit.*
· *Australia's largest bank by assets, Commonwealth Bank of Australia, is moving 50 staff to Amsterdam as it readies for Brexit, according to The Financial Times.*
· *Others including Macquarie, Westpac, and ANZ Bank are making plans on the continent.*
· *Many foreign financial institutions are frustrated — like many UK businesses — by the lack of any real clarity over what sort of Brexit the UK will actually achieve when the Article 50 period runs out in March next year.*
Australian banks with UK operations are beginning to put in motion plans to shift staff and other assets out of London as the possibility of a no-deal Brexit looms large in their thoughts.
According to a story from the Financial Times on Monday, Australia's largest bank by assets, Commonwealth Bank of Australia (CBA), has set in motion plans to shift 50 staff from London to the Dutch capital, Amsterdam, and has applied for a banking licence in the country.
Those staff will be focused on the bank's European "passporting" operations — the system by which banks are able to operate across EU borders while possessing just a single banking licence. The financial passport is linked strongly to membership of the European Single Market, and the UK will lose its passporting rights as a result.
Commonwealth Bank said on Monday that its plan to shift staff to Amsterdam is being put in place "to ensure we can continue to provide the best service to our customers, while limiting disruption to existing business and our employees.
While Commonwealth Bank is the latest bank to pull the trigger on moving staff, other Australian lenders are also shifting some capacity away from the UK, with investment bank Macquarie saying in May that it plans to expand its operations in Dublin, Ireland as a protection from Brexit. Westpac and ANZ are also shifting some operations to continental Europe.
Many foreign financial institutions are frustrated — like many UK businesses — by the lack of any real clarity over what sort of Brexit the UK will actually achieve when the Article 50 period runs out in March next year.
The British government remains adamant that it will strike a deal, and says one is 95% complete, but the exact shape of that deal isn't entirely clear. There are also lingering fears that negotiations could collapse at any moment, leaving the UK facing down a no deal Brexit, seen by the businesses, and the financial sector in particular, as the worst possible outcome.
No deal would be particularly catastrophic for banks and other financial institutions because of the highly internationalized nature of the sector, which sees hundreds of billions of dollars flow across borders every single day.
Australian lenders are not alone in their desire for clarity. While most of the attention around post-Brexit job relocations out of the City has focused on American and European lenders, banks from around the world using London as a hub for their EU business have been made to decide what to do post Brexit, with Japanese banks particularly active in moving staff out of the UK.
Sumitomo Mitsui, MUFJ, Daiwa Securities, and Nomura are among the Japanese banks with plans in motion to shift some of their staff and physical operations out of the UK, generally to Frankfurt, after Brexit.
*SEE ALSO: Europe is closing a trading loophole that banks were relying to cope with Brexit*
Join the conversation about this story »
NOW WATCH: This company spent 10 years developing a product that allows humans to scale walls like a gecko Reported by Business Insider 44 minutes ago.
↧
More Pages to Explore .....
